This study focused on engineering an antagonistic anti-c-MET antibody capable of blocking HGF/c-MET signaling and inducing the killing of MET-overexpressing cancer cells through antibody-dependent cellular cytotoxicity (ADCC). Here, HGF is linked to cancer.